PainReform logo

PainReformNASDAQ: PRFX

Profile

Sector:

Healthcare

Country:

Israel

IPO:

01 September 2020

Next earnings report:

09 August 2024

Last dividends:

N/A

Next dividends:

N/A
$1.21 M
-93%vs. 3y high
3%vs. sector
-vs. 3y high
-vs. sector
-74%vs. 3y high
31%vs. sector
-vs. 3y high
-vs. sector

Price

pre-market | 35 min ago
$0.49-$0.01(-2.38%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

PRFX Latest News

PainReform to Present at the Microcap Conference in Atlantic City
GlobeNewsWire22 January 2024 Sentiment: POSITIVE

TEL AVIV, Israel, Jan. 22, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. ( Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that management will be participating at The Microcap Conference which is being held on January 30 - February 1, 2024 at Caesars Atlantic City Hotel & Casino in Atlantic City, NJ.

Why Is PainReform (PRFX) Stock Up 38% Today?
InvestorPlace20 July 2023 Sentiment: POSITIVE

PainReform (NASDAQ: PRFX ) stock is rallying on Thursday after the pharmaceutical company regained compliance with Nasdaq listing requirements. According to the company's press release, it was sent notice of it regaining compliance on July 18.

PRFX Stock: The $2.7 Million Reason PainReform Is Up 100% Today
InvestorPlace14 July 2023 Sentiment: POSITIVE

In the world of biotech stocks, one company that's generating big buzz today is PainReform (NASDAQ: PRFX ). The Israeli clinical-stage pharmaceutical company has seen its stock price absolutely skyrocket.

Why Is PainReform (PRFX) Stock Down 40% Today?
InvestorPlace12 July 2023 Sentiment: NEGATIVE

PainReform (NASDAQ: PRFX ) stock is falling on Wednesday after the company announced a concurrent registered direct offering and private placement. The registered direct offering has PainReform agreeing to sell 301,230 shares of PRFX stock at a price of $9 per share.

What type of business is PainReform?

PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company is currently conducting two Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. PainReform Ltd. was incorporated in 2007 and is based in Tel Aviv, Israel.

What sector is PainReform in?

PainReform is in the Healthcare sector

What industry is PainReform in?

PainReform is in the Drug Manufacturers - Specialty & Generic industry

What country is PainReform from?

PainReform is headquartered in Israel

When did PainReform go public?

PainReform initial public offering (IPO) was on 01 September 2020

What is PainReform website?

https://www.painreform.com

Is PainReform in the S&P 500?

No, PainReform is not included in the S&P 500 index

Is PainReform in the NASDAQ 100?

No, PainReform is not included in the NASDAQ 100 index

Is PainReform in the Dow Jones?

No, PainReform is not included in the Dow Jones index

When does PainReform report earnings?

The next expected earnings date for PainReform is 09 August 2024